Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities
暂无分享,去创建一个
O. Mir | F. Goldwasser | P. Beuzeboc | M. Zerbib | L. Guillevin | S. Ropert | J. Alexandre | T. Flam | D. Amsellem-Ouazana | B. Debré
[1] D. Bailey,et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] M. Dimopoulos,et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Doroshow,et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Vale. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.
[6] S. Culine,et al. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study. , 2003, Anticancer research.
[7] D. Roychowdhury,et al. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Goldwasser,et al. Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] S. Ricci,et al. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum‐based regimens , 2002, Cancer.
[10] S. Novello,et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] F. Goldwasser,et al. Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients. , 2002, European journal of cancer.
[12] P. Hammel,et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] T. Petit,et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Ahmedin Jemal,et al. Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.
[15] H. Gurney,et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] F. Goldwasser,et al. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] P. Albers,et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Eastham,et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Dimopoulos,et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] M. Mazumdar,et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] E. Raymond,et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines , 1999, Cancer Chemotherapy and Pharmacology.
[22] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[23] F. Lévi,et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. , 1990, Journal of the National Cancer Institute.
[24] N. Geller,et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.
[25] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[26] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[27] A. Satterfield,et al. TREATMENT , 1924, California and western medicine.